Novartis says heart-failure drug wins faster review in Europe
November 28, 2014 at 01:44 AM EST
ZURICH, Nov 28 (Reuters) - Novartis' new heart failure drug was granted a speedier evaluation by the European health regulator, shortening the review by 60 days, the Swiss drugmaker said on Friday.
